2023
DOI: 10.1089/jwh.2022.0342
|View full text |Cite
|
Sign up to set email alerts
|

Determinants of Hormone Replacement Therapy Knowledge and Current Hormone Replacement Therapy Use

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
2
0

Year Published

2023
2023
2024
2024

Publication Types

Select...
5

Relationship

0
5

Authors

Journals

citations
Cited by 5 publications
(2 citation statements)
references
References 33 publications
0
2
0
Order By: Relevance
“…In a 2023 Food and Drug Administration report, although 82% of US women older than 45 years reported at least one menopausal symptom, only 10.5% had used any form of menopausal HT. 43 Chlebowski and Aragaki 3 now maintain that estrogen is not the culprit behind breast cancer, adding MPA is what raises the risk. We are aware that estrogen alone, or together with MPA, has been reported to stimulate breast epithelial cell proliferation 44 and, by increasing breast density overall, can lead to frequent mammography, resulting in early detection of existing breast cancers.…”
Section: Hormone Therapy and Breast Cancermentioning
confidence: 99%
See 1 more Smart Citation
“…In a 2023 Food and Drug Administration report, although 82% of US women older than 45 years reported at least one menopausal symptom, only 10.5% had used any form of menopausal HT. 43 Chlebowski and Aragaki 3 now maintain that estrogen is not the culprit behind breast cancer, adding MPA is what raises the risk. We are aware that estrogen alone, or together with MPA, has been reported to stimulate breast epithelial cell proliferation 44 and, by increasing breast density overall, can lead to frequent mammography, resulting in early detection of existing breast cancers.…”
Section: Hormone Therapy and Breast Cancermentioning
confidence: 99%
“…Actually, breast cancer incidence rates in the United States have increased by roughly 0.5% annually since the premature termination of the WHI's CEE+MPA trial in 2002, 42 even though HT use has remained low. In a 2023 Food and Drug Administration report, although 82% of US women older than 45 years reported at least one menopausal symptom, only 10.5% had used any form of menopausal HT 43 …”
Section: The Whi's Misleading Assertion That Its Findings Reduced The...mentioning
confidence: 99%